In this program, a panel of experts in the management of diabetes educate healthcare providers on teplizumab’s role in delaying type 1 diabetes stage progression through early intervention. It covers disease staging, screening recommendations, eligibility processes, teplizumab’s mechanism of action, and the navigation of the 14-day infusion regimen. By facilitating timely teplizumab access, the program aims to identify at-risk patients, reduce diabetic ketoacidosis, mitigate disease burdens, and improve quality of life.

In this program, a panel of experts in the management of diabetes educate healthcare providers on teplizumab’s role in delaying type 1 diabetes stage progression through early intervention. It covers disease staging, screening recommendations, eligibility processes, teplizumab’s mechanism of action, and the navigation of the 14-day infusion regimen. By facilitating timely teplizumab access, the program aims to identify at-risk patients, reduce diabetic ketoacidosis, mitigate disease burdens, and improve quality of life.